Erez Vigodman - Teva Pharmaceutical CEO
| TEVA Stock | ILA 4,978 25.00 0.50% |
CEO
Mr. Erez Vigodman serves as President, Chief Executive Officer and Director at Teva Pharmaceutical Industries Limited since February 11, 2014 after joining Tevas Board of Directors in 2009. From 2010 to 2014, he served as President and Chief Executive Officer of Adama Agricultural Solutions Ltd. . From 2001 to 2009, he served as President and Chief Executive Officer of Strauss Group Ltd. Mr. Vigodman is a member of the Advisory Committee to the Israel National Economic Council and the International Advisory Board of the Israel Science Technology Innovation Policy Institute. Mr. Vigodman received a Bachelors degree in Accounting and Economics from Tel Aviv University in 1987 and is a graduate of the program of Management Development at Harvard Graduate School of Business Administration. Mr. Vigodman is a certified public accountant. since 2014.
| Age | 55 |
| Tenure | 10 years |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CEO Age | ||
| Anat CohenDayag | Compugen | 56 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moshe Many, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Janet Vergis, Independent Director | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Abbas Hussain, Independent Director | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Andrew Weil, Chief Accounting Officer | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director | ||
| Nechemia Peres, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Joseph Nitzani, Independent Director | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Sigurdur Olafsson, President and CEO - Global Generic Medicines Group | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, Chief Financial Officer, Executive Vice President | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Eli Kalif, Chief Financial Officer, Executive Vice President, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |